4892
Cyfuse Biomedical K.K.
サイフューズ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Dec 2022
374,477
Dec 2023
61,112
Dec 2024
54,446
Dec 2025
230,999
Operating profit(thousand JPY)
Dec 2022
-425,089
Dec 2023
-697,437
Dec 2024
-896,133
Dec 2025
-828,179
Operating profit margin(%)
Dec 2022
-113.52
Dec 2023
-1,141.24
Dec 2024
-1,645.91
Dec 2025
-358.52
Profit before tax(thousand JPY)
Dec 2022
-471,953
Dec 2023
-586,187
Dec 2024
-869,747
Dec 2025
-761,301
Profit(thousand JPY)
Dec 2022
-473,962
Dec 2023
-589,211
Dec 2024
-872,238
Dec 2025
-763,843
Total assets(thousand JPY)
Dec 2022
4,815,337
Dec 2023
4,214,809
Dec 2024
3,518,001
Dec 2025
4,266,026
Cash and cash equivalents(thousand JPY)
Dec 2022
3,437,307
Dec 2023
2,873,773
Dec 2024
2,052,570
Dec 2025
2,376,535
Cash flows from operating activities(thousand JPY)
Dec 2022
-403,596
Dec 2023
-562,296
Dec 2024
-760,553
Dec 2025
-534,793
Cash flows from investing activities(thousand JPY)
Dec 2022
-430,674
Dec 2023
-19,474
Dec 2024
-8,637
Dec 2025
-397,564
Cash flows from financing activities(thousand JPY)
Dec 2022
2,658,538
Dec 2023
18,236
Dec 2024
-52,012
Dec 2025
1,256,323
Return on equity(-)
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2022
78.3
Dec 2023
76
Dec 2024
70.9
Dec 2025
62.3
Earnings per share(JPY per share)
Dec 2022
-177.67
Dec 2023
-75.42
Dec 2024
-108.34
Dec 2025
-86.78
Net assets per share(JPY per share)
Dec 2022
484.88
Dec 2023
405.71
Dec 2024
304.6
Dec 2025
276.42
Dividend per share(-)
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.